Orelabrutinib ( DrugBank: Orelabrutinib )

4 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3
49	Systemic lupus erythematosus	1
61	Autoimmune hemolytic anemia	1
63	Idiopathic thrombocytopenic purpura	2

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057880	2022-04-01	2022-03-20	A prospective, self-controlled study to explore efficacy and safety of orelabrutinibin AQP4-IgG posi ...	A prospective, self-controlled study to explore efficacy and safety of orelabrutinibin AQP4-IgG posi ...	Neuromyelitis optica spectrum disorder	Case group:Orelabrutinib, orally, 50 mg QD;	Peking Union Medical College Hospital	NULL	Pending	18	75	Both	Case group:23;	Phase 1	China
2	NCT05284175 (ClinicalTrials.gov)	April 2022	9/3/2022	A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder	A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinibin AQP4-IgG Posi ...	Neuromyelitis Optica Spectrum Disorder	Drug: Orelabrutinib	Peking Union Medical College Hospital	Beijing InnoCare Pharma Tech Co., Ltd.;GCP ClinPlus Co., Ltd.	Not yet recruiting	18 Years	75 Years	All	23	N/A	China
3	NCT04711148 (ClinicalTrials.gov)	March 1, 2021	8/1/2021	A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinibin Patients With Relaps ...	Relapsing Remitting Multiple Sclerosis	Other: placebo;Drug: orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Active, not recruiting	18 Years	55 Years	All	160	Phase 2	United States;China;Poland;Ukraine

First Previous1Next Last

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05688696 (ClinicalTrials.gov)	March 31, 2023	10/1/2023	Evaluate the Efficacy and Safety of Orelabrutinibin Adult Patients With Systemic Lupus Erythematosus ...	A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficac ...	Systemic Lupus Erythematosus, SLE	Drug: Orelabrutinib (Low Dose);Drug: Orelabrutinib (High Dose);Drug: Orelabrutinib Placebo	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Not yet recruiting	18 Years	75 Years	All	186	Phase 2	China

First Previous1Next Last

61. Autoimmune hemolytic anemia

Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100045594	2021-04-19	2021-04-19	A single center prospective clinical study of Orelabrutinibin the treatment of relapsed/refractory a ...	A single center prospective clinical study of Orelabrutinibin the treatment of recurrent refractory ...	Relapsed/refractory autoimmune hemolytic anemia /Evans syndrome	Single arm:Orelabrutinib;	Tianjin Medical University General Hospital	NULL	Recruiting			Both	Single arm:20;	Phase 4	China

First Previous1Next Last

63. Idiopathic thrombocytopenic purpura

Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05232149 (ClinicalTrials.gov)	February 21, 2022	20/12/2021	A Study to Evaluate the Efficacy and Safety of Orelabrutinibin Adult Patients With Immune Thrombocyt ...	A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orel ...	Primary Immune Thrombocytopenia	Drug: Orelabrutinib( lower dose);Drug: Orelabrutinib( higher dose)	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Recruiting	18 Years	80 Years	All	30	Phase 2	China
2	NCT05020288 (ClinicalTrials.gov)	September 1, 2021	12/8/2021	A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP	A Prospective, Open-label, Multicenter,Single-armed Study of Orelabrutinibin the Treatment of Refrac ...	Immune Thrombocytopenia;Bruton's Tyrosine Kinase	Drug: Orelabrutinib	Shandong University	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 2	NULL

First Previous1Next Last